Pharmaceuticals Trio Draw Buy Ratings Ahead of 2026 Catalysts
A trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
Discover easy ways to earn fast cash without much effort. Explore these options to quickly boost your finances!
21,845 articlesA trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
A major fund just boosted its stake in a struggling auto-parts retailer. This article breaks down what the move could...
Lucid’s Gravity starts at $95,000 with a 450-mile range, claiming superiority over high-powered ICE rivals. The compa...
Bitcoin traders grapple with a tightening macro backdrop as the Fed's liquidity cushion shrinks, signaling tighter fu...
Geopolitical tensions and stubborn inflation are rattling markets. Even higher-income americans turning cautious sign...
Tripadvisor (TRIP) entered 2026 with a clear path: optimize advertising, expand bookings, and monetize experiences. I...
Strategy unveils a private repurchase of roughly $1.5 billion in convertible notes, funded by cash, ATM proceeds, and...
Institutional moves can quietly reshape a stock's risk and reward. This article looks at Levin's trim of O-I Glass an...
Costco faces a pivotal question for 2029: can it sustain double-digit earnings growth and margin resilience to lift C...
In a year of AI-driven consolidation, three enterprise software names are walling off attention as potential takeout ...
A new projection shows how a $400,000 investment in SCHD could generate roughly $50,000 of annual dividends over 15 y...
June market swings have hit chip names hard, but the smarter money is shifting toward a single AI-dominant tech heavy...